Synthetic vaccines represent a promising avenue in cancer immunotherapy by promoting targeted immune responses. Liposomal technologies have further advanced synthetic vaccinology by enabling the efficient delivery of tumor‐associated carbohydrate antigens. Despite this progress, the toxicity and reproducibility of such platforms remain underexplored. In this preliminary study, we synthesized a series of neoglycolipids bearing the Thomsen–Nouveau (Tn) antigen using bio‐orthogonal thiol–ene click chemistry. Here we present the results obtained using a set of neoglycolipids that were evaluated for their ability to self‐assemble into liposomal vesicles and for in vitro cytotoxicity. The resulting neoglycolipids exhibited no detectable cytotoxicity and formed stable liposomal structures when formulated with palmitic acid and 1‐palmitoyl‐2‐oleoyl‐ sn ‐glycero‐3‐phosphocholine via a freeze–thaw/extrusion process. This early‐stage work presents a proof of concept for a tunable, liposomal‐based synthetic vaccine platform.
Mebarek et al. (Thu,) studied this question.